Address
Kiryat Hadassah Minrav Building
Jerusalem, 9112002
Israel
Phone
972 2 532 7151
Website
Sector
Healthcare
Industry
Biotechnology
Employees
18
First IPO Date
June 28, 2018
| Name | Title | Pay | Year Born |
| Miranda J. Toledano | Chief Executive Officer & Director | 562,000 | 1977 |
| Dana Yaacov-Garbeli | Chief Financial Officer | 226,000 | 1983 |
| Gregory Burshtein | Chief of Research & Development | 254,000 | 1977 |
| Hillel Galitzer | Chief Operating Officer | 307,000 | 1978 |
| Constantin Itin | Head of Biopharmaceutics & Bioanalytics | 0 | N/A |
| Rachel Wagman | Chief Clinical Advisor | 0 | N/A |
| Cherin Smith | Executive Vice President & Head of Clinical Operations | 0 | N/A |
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.